Search Results for "retail"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for retail. Results 131 to 140 of 361 total matches.

Macitentan (Opsumit) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2014  (Issue 1436)
by FDB, Inc. All rights reserved. ©2014. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail ...
The FDA has approved macitentan (ma" si ten' tan; Opsumit – Actelion), for oral treatment of pulmonary arterial hypertension (PAH). Macitentan is the second nonselective endothelin receptor antagonist approved for PAH. It is a derivative of bosentan (Tracleer), which is also manufactured by Actelion, and is scheduled to become available generically in 2015. Riociguat (Adempas), another new drug for this indication, will be reviewed in a future issue. Volibris
Med Lett Drugs Ther. 2014 Feb 17;56(1436):15-6 |  Show IntroductionHide Introduction

Anoro Ellipta: An Inhaled Umeclidinium/Vilanterol Combination for COPD

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 2014  (Issue 1440)
. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices may be higher. 2. Only the 250/50 mcg strength ...
The FDA has approved an inhaled fixed-dose combination of the long-acting anticholinergic umeclidinium (ue mek" li din' ee um) and the long-acting beta2-adrenergic agonist (LABA) vilanterol (Anoro Ellipta – GSK/Theravance) for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD). Anoro Ellipta is the first product available in the US that combines two long-acting bronchodilators in a single delivery device.
Med Lett Drugs Ther. 2014 Apr 14;56(1440):30-1 |  Show IntroductionHide Introduction

Sublingual Immunotherapy for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014  (Issue 1444)
. All rights reserved. ©2014. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices ...
The FDA has approved 3 allergen extracts for sublingual administration as immunotherapy for allergic rhinitis confirmed by a positive skin test or in vitro testing for pollen-specific IgE antibodies: Oralair (Stallergenes S.A./Greer) and Grastek (Merck) for grass pollen-induced allergic rhinitis and Ragwitek (Merck) for short ragweed pollen-induced allergic rhinitis.
Med Lett Drugs Ther. 2014 Jun 9;56(1444):47-8 |  Show IntroductionHide Introduction

Tobramycin Inhalation Solution (Bethkis) for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2014  (Issue 1445)
. ©2014. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices may be higher. 3. Doses ...
The FDA has approved another solution of the aminoglycoside antibiotic tobramycin (Bethkis – Chiesi/Cornerstone) for oral inhalation via a nebulizer for management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa.
Med Lett Drugs Ther. 2014 Jun 23;56(1445):51-2 |  Show IntroductionHide Introduction

Luliconazole Cream (Luzu) for Tinea Infections

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2014  (Issue 1445)
, Inc. All rights reserved. ©2014. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices ...
The FDA has approved luliconazole (Luzu Cream, 1% – Valeant) for treatment of tinea pedis, tinea cruris, and tinea corporis infections.
Med Lett Drugs Ther. 2014 Jun 23;56(1445):50-1 |  Show IntroductionHide Introduction

Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events

   
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014  (Issue 1451)
retail prices may be higher. 2. Zontivity is available as 2.5-mg vorapaxar sulfate tablets, equivalent ...
The FDA has approved vorapaxar (Zontivity – Merck), an oral protease-activated receptor-1 (PAR-1) antagonist, for use with aspirin and/or clopidogrel to reduce the risk of thrombotic cardiovascular events in patients with peripheral arterial disease or a history of myocardial infarction (MI). It is the first PAR-1 antagonist to be approved by the FDA.
Med Lett Drugs Ther. 2014 Sep 15;56(1451):85-6 |  Show IntroductionHide Introduction

Efinaconazole Topical Solution (Jublia) for Onychomycosis

   
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014  (Issue 1451)
. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices may be higher. 3. Dosage adjustment ...
The FDA has approved efinaconazole 10% solution (Jublia – Valeant) for topical treatment of toenail onychomycosis due to Trichophyton rubrum and/or Trichophyton mentagrophytes. It is the first topical triazole antifungal drug to be approved for this indication. A topical oxaborole antifungal solution, tavaborole 5% (Kerydin – Anacor), also recently approved by the FDA for the same indication will be reviewed in a future issue.
Med Lett Drugs Ther. 2014 Sep 15;56(1451):88-9 |  Show IntroductionHide Introduction

An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019  (Issue 1566)
to Sandoz, Symjepi will be made available first to institutions and later to the retail market ...
The FDA has approved a manually injected, single-dose, prefilled epinephrine syringe (Symjepi – Adamis/Sandoz) for emergency treatment of anaphylaxis. The new device is approved in 0.3- and 0.15-mg strengths for treatment of patients weighing ≥30 kg and 15 to 30 kg, respectively; only the 0.3-mg strength is currently available. According to Sandoz, Symjepi will be made available first to institutions and later to the retail market.
Med Lett Drugs Ther. 2019 Feb 25;61(1566):25-6 |  Show IntroductionHide Introduction

Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D) (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
January 12, 2025. Individual retailers may have their own generic products. 3. Dosage adjustments ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3   doi:10.58347/tml.2025.1721f |  Show IntroductionHide Introduction

Colesevelam (Welchol) For Hypercholesterolemia

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2000  (Issue 1091)
based on AWP listings in Drug Topics Red Book Update,October 2000. Retail prices may be higher or lower ...
Colesevelam hydrochloride (Welchol - Sankyo Pharma), a nonabsorbed hydrophilic polymer that binds bile acids, has been approved by the FDA for reduction of plasma LDL cholesterol in patients with primary hypercholesterolemia.
Med Lett Drugs Ther. 2000 Oct 30;42(1091):102-4 |  Show IntroductionHide Introduction